Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Trial Profile

Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Dapagliflozin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms BEYOND
  • Sponsors AstraZeneca
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 28 Apr 2017 Planned End Date changed from 1 Apr 2018 to 23 Jan 2018.
    • 28 Apr 2017 Planned primary completion date changed from 1 Apr 2018 to 23 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top